STP 705

Drug Profile

STP 705

Alternative Names: Anti-fibrosis RNA interference therapeutic - Sirnaomic; Cotsiranib; STP 705; STP-705LU; STP-705LV

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Developer General Research Laboratory; Guangzhou Xiangxue Pharmaceuticals; Sirnaomics
  • Class Anti-inflammatories; Antifibrotics; Small interfering RNA; Stem cell therapies
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic scars
  • Preclinical Cholangiocarcinoma; Hepatic fibrosis; Wounds

Most Recent Events

  • 06 Dec 2017 Preclinical trials in Cholangiocarcinoma in USA before December 2017
  • 06 Dec 2017 STP 705 receives Orphan Drug status for Cholangiocarcinoma in USA
  • 01 Aug 2017 STP 705 receives Orphan Drug status for Primary sclerosing cholangitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top